Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.42 |
| ▸ | RXRG | P48443 | 6/20 | 0.41 |
| ▸ | RXRA | P19793 | 5/20 | 0.41 |
| ▸ | RXRB | P28702 | 5/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.40 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 7/20 | 0.39 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4424009 | 0.90 | TRPM2 (0.40) | FFAR1RXRGRXRARXRBFFAR4 | |
| SCHEMBL4427558 | 0.86 | FFAR4 (0.49) | FFAR1FFAR4FFAR2PPARDPPARA | |
| SCHEMBL1549165 | 0.82 | PPARD (0.59) | FFAR1FFAR4PPARDPPARAPPARG | |
| SCHEMBL1549554 | 0.82 | FFAR4 (0.46) | FFAR1FFAR4FFAR2PPARDPPARA | |
| SCHEMBL4422263 | 0.78 | RXRG (0.48) | FFAR1RXRGRXRARXRBFFAR4 | |
| SCHEMBL27642969 | 0.77 | PPARD (0.53) | FFAR1RXRAFFAR4PPARDPPARA | |
| SCHEMBL4430360 | 0.76 | PPARG (0.41) | FFAR4PPARDPPARAPPARG | |
| SCHEMBL1227421 | 0.76 | PTGDR2 (0.41) | FFAR1RXRGRXRARXRB | |
| SCHEMBL1549973 | 0.75 | PPARD (0.47) | PPARDPPARAPPARG | |
| SCHEMBL27664131 | 0.75 | GSTP1 (0.42) | FFAR4PPARDPPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495001-B2 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | claimed |
| JP-2007509998-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682507-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | claimed |
| WO-2005049572-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | claimed |
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | claimed |
| US-7495001-B2 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1682507-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049572-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | FFAR1 10/4885RXRG 13/4885RXRA 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.